Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
Drug, Healthcare and Patient Safety · 2024-06 · Volume 16 · 51-59
DOI: 10.2147/dhps.s372239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug, Healthcare and Patient Safety, 2024-06. Verfasst von Steven J Cassady und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary & Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary & Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
- Department of Internal Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
- Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Gautam V Ramani
Zitieren
APA
Cassady, S. J., Almario, J. A. N., & Ramani, G. V. (2024). Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date. Drug, Healthcare and Patient Safety, Volume 16, 51-59. https://doi.org/10.2147/dhps.s372239
Vancouver
Cassady SJ, Almario JAN, Ramani GV. Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date. Drug, Healthcare and Patient Safety. 2024;Volume 16:51-59. doi:10.2147/dhps.s372239
BibTeX
@article{Cassady2024,
author = {Cassady, Steven J and Almario, Jose Alejandro N and Ramani, Gautam V},
title = {Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date},
journal = {Drug, Healthcare and Patient Safety},
year = {2024},
volume = {Volume 16},
pages = {51--59},
doi = {10.2147/dhps.s372239}
}
EUVIMED